Many analysts say Celgene is currently undervalued. Currently the company is being followed by 16 researchers. The recommendations spread over: no sells, 8 times hold and 8 times buy. The average of the current target prices for the stock is at 138,12 USD. This is at around 36 percent more than the current price of 102,17 USD. The most recent recommendations for the biotech company are from Morgan Stanley , Cantor Fitzgerald and Piper Jaffray.
Based on the current number of shares Celgene 's market capitalization equals 80,37 billion USD.
At 22.00 the stock trades 0,55 percent higher at 102,17 USD.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.